Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome a pharmacodynamic randomised study

Thrombosis and Haemostasis

Volumn 111, Issue 2, 2013, Pages 273-278

  Laine, Marc ^a   Frere, Corinne ^d   Toesca, Richard ^b   Berbis, Julie ^c   Barnay, Pierre ^e   Pansieri, Michel ^e   Michelet, Pierre ^b   Bessereau, Jacques ^b   Camilleri, Elise ^f   Ronsin, Olivia ^a   Helal, Olfa ^a   Paganelli, Franck ^a   Dignat George, Françoise ^d   Bonello, Laurent ^a,d  

^a HÔPITAL NORD   (France)

^b TIMONE HOSPITAL   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d INSERM   (France)

^e Service de Cardiologie   (France)

^f Hôpital de Martigues   (France)

Author keywords

Acute coronary syndrome; Diabetes mellitus; P2Y12 receptor blockade; Percutaneous coronary intervention; VASP index

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; PRASUGREL; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOGENIC SHOCK; DIABETES MELLITUS; FEMALE; FLOW CYTOMETRY; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; DIABETES MELLITUS; P2Y12 RECEPTOR BLOCKADE; PERCUTANEOUS CORONARY INTERVENTION; VASP INDEX;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELL ADHESION MOLECULES; DIABETES MELLITUS; FEMALE; FRANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHOPROTEINS; PILOT PROJECTS; PIPERAZINES; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2Y12; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893195154     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-05-0384     Document Type: Article

References (29)

1. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of anti-platelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.
2. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
3. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
4. Aradi D, Komócsi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J 2010; 160: 543-551.
5. Järemo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-238.
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435.
7. Erlinge D, Varenhorst C, Braun O, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52: 1968-1977.
8. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischaemic events. Diabetes Care 2003; 26: 2181-2188.
9. Andersson C, Lyngbæk S, Nguyen CD, et al. Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. J Am Med Assoc 2012; 308: 882-889.
10. Storey R F, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56: 1456-1462.
11. TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753-1763.
12. PLATelet inhibition and patient Outcomes Investigators. Comparison of ti-cagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293.
13. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
14. Alexopoulos D, Xanthopoulou I, Mavronasiou E, et al. Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes Mellitus. Diabetes Care 2013; Epub ahead of print.
15. Schwarz UR, Geiger J, Walter U, et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets- definition and detection of ticlopi-dine/clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152.
16. Bonello L, Mancini J, Pansieri M, et al. Relationship between post-treatment platelet reactivity and ischaemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012; 10: 1999-2005.
17. CHAMPION PHOENIX Investigators. Effect of Platelet Inhibition with Can-grelor during PCI on Ischaemic Events. N Engl J Med 2013; Epub ahead of print.
18. Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangre-lor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 2012; 34: 44-55.
19. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Car-diol 2013; 61: 1601-1606.
20. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized Assessment of Ti-cagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment-Elev-ation Myocardial Infarction. Circ Cardiovasc Interv 2012; 5: 797-804.
21. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS Registry. Circulation 2000; 102: 1014-1019.
22. Marso S P, Giorgi LV, Johnson WL, et al. Diabetes mellitus is associated with a shift in the temporal risk profile of in-hospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. Am Heart J 2003; 145: 270-277.
23. Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52: 743-749.
24. TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636.
25. PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010; 31: 3006-3016.
26. Judge HM, Buckland RJ, Sugidachi A, et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103: 1210-1217.
27. Bouman HJ, Parlak E, van Werkum J W, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 8: 482-488.
28. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250-256.
29. Barragan P, Paganelli F, Camoin-Jau L, et al. Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity. Thromb Haemost 2010; 104: 410-411.